MI

Mahesh Inderpal Singh

Director DIN 02679896
DIN 02679896 First appointment Jun 2009
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jun 2009
Shareholding value β€’β€’β€’β€’ Premium profile

About Mahesh Inderpal Singh

Data last updated:

Mahesh Inderpal Singh was a Director at Cancure Clinics Private Limited (from 2013) and Director at Regpak Biopharma Private Limited (from 2009).

DIN 02679896
First Appointment 30 Jun 2009
Oldest Company Age 17 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cancure Clinics Private Limited U51397CH2013PTC034443
Director16 Apr 20132013Strike Off
Regpak Biopharma Private Limited U24232CH2009PTC031673
Director30 Jun 20092009Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Cancure Clinics Private Limited
Regpak Biopharma Private Limited
Premium access

Shareholding and investment profile for Mahesh Inderpal Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mahesh Inderpal Singh

Mahesh Inderpal Singh was first appointed on 30 Jun 2009 as Director at Regpak Biopharma Private Limited. The most recent appointment on record is 16 Apr 2013 at Cancure Clinics Private Limited.

Mahesh Inderpal Singh held 2 earlier board appointments: Cancure Clinics Private Limited (Director, from 16 Apr 2013); Regpak Biopharma Private Limited (Director, from 30 Jun 2009).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available